The recommended starting dose of tirzepatide is 2.5 mg injected subcutaneously once weekly. Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions.​ The 2.5 mg dosage is for treatment initiation and is not intended for glycemic control.1

After 4 weeks, increase the dose to 5 mg once weekly.1

If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose.1

The maximum dose of tirzepatide is 15 mg once weekly.1

Administer tirzepatide

• once weekly
• any time of day, and
• with or without food.1

Tirzepatide should be injected subcutaneously in the abdomen, thigh, or upper arm.1

In the phase 3 SURPASS studies, participants were assigned to 1 of 3 tirzepatide treatment arms (5, 10, or 15 mg) for assessment of efficacy and safety (Dose Escalation Schedule for Tirzepatide in Phase 3 Clinical Studies).1

The starting dose of tirzepatide was 2.5 mg once weekly for 4 weeks and escalated in 2.5 mg increments every 4 weeks until the assigned dose was achieved.2

Dose escalation in 2.5 mg increments at 4 week intervals was chosen based on the ability to improve the tolerability profile.2

The 3 tirzepatide doses (5, 10, and 15 mg) studied for efficacy in the SURPASS phase 3 clinical study program were identified based on the safety, efficacy, and exposure response modeling of data in participants with T2D in phase 1 and 2 studies.2